RecruitingNCT06759961
Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant Centre
Studying Thrombotic microangiopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Principal Investigator
- Giorgia Comai, MDIRCCS Azienda Ospedaliero-Universitaria di Bologna
- Enrollment
- 250 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2033
Study locations (1)
- IRCCS Sant'Orsola University Hospital - Nephrology, Dialysis and Transplant Unit, Bologna, BO, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06759961 on ClinicalTrials.govOther trials for Thrombotic microangiopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07059026Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult PatientsITAC (Instituto de Trasplantes y Alta Complejidad)
- RECRUITINGNCT06102694Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic MicroangiopathyInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE4NCT05743400Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell TransplantationHospices Civils de Lyon
- ACTIVE NOT RECRUITINGPHASE3NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantAlexion Pharmaceuticals, Inc.